Skip to main content

Arrowhead Files to Begin Phase IIa Trial of HBV Drug


Arrowhead Research last month said that it has submitted a regulatory application seeking clearance to begin a phase IIa study of its RNAi-based hepatitis B treatment ARC-520.

ARC-520 comprises two distinct siRNAs targeting highly conserved genomic regions across the major HBV genotypes, and is formulated with a proprietary delivery technology called dynamic polyconjugates.

The planned phase IIa trial is slated to run in Hong Kong and test single, escalating doses of ARC-520 in combination with the antiviral entecavir in order to determine the "depth and duration of hepatitis B surface antigen reduction," according to Arrowhead.

In October, Arrowhead announced that preliminary phase I data showed the drug to be safe enough to advance into the next stage of human testing.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.